TheEdgeResearch
Home / Stocks / PHYOF

IXICO plc (PHYOF)

OTC Healthcare Biotechnology
$0.07 ▲ +0.00%
Market Cap
$6.5M
Sector
Healthcare
Industry
Biotechnology
Beta
0.11
52-Wk Range
0.07-0.15
CEO
Bram Goorden
Country
GB
Currency
USD

IXICO plc operates in the Biotechnology industry of the Healthcare sector, headquartered in London, GL, GB. The stock last traded at $0.07, up 0.00% on the session, giving a market capitalisation of $6.5M. On trailing twelve-month figures it carries a trailing P/E of -6.63, a net margin of -25.0%. Its beta of 0.11 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-6.63
Price / Sales
3.91
Price / Book
1.12
EV / EBITDA
-11.71
Gross margin
48.3%
Operating margin
-35.7%
Net margin
-25.0%
Return on equity
—
Debt / equity
0.05
Current ratio
2.83
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
79
IPO date
1997-01-23
Headquarters
London, GL, GB
About IXICO plc

IXICO plc, a London-based company established in 1995, specializes in providing data analytics services to the global biopharmaceutical industry. Operating across the UK, Europe (including Switzerland, Netherlands, Ireland), the United States, and internationally, IXICO supports clinical trials by managing the entire lifecycle of study-generated data, from acquisition and processing to in-depth analysis and comprehensive reporting. They leverage proprietary technology platforms like Assessa, a secure digital tool that aids clinical decision-making for patient selection and post-market monitoring, and TrialTracker, which streamlines intricate imaging workflows, handling everything from initial image uploads and quality control to expert analysis, interpretation, and final data delivery within clinical research. IXICO's expertise is concentrated on neurological disorders, including Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis and other demyelinating conditions, Progressive Supranuclear Palsy, and various rare neurological diseases. Their services encompass not only the collection, optimization, and analytics for rare neurological disorders but also drug development analytics, specialized imaging operations, post-market surveillance support, and expert consultancy. The company delivers comprehensive, end-to-end services for clinical trials, covering initial trial design and consultation, meticulous project management, imaging site setup and management, robust data management, expert image reading and analysis, and guidance on regulatory pathways.

Comparable companies

IXICO plc is most often compared with the following Healthcare names:

ATOSDGTLFEGMMFERNAIRDOMERPTRRF
More research on PHYOF
PHYOF technical analysis PHYOF TheEdge Score Compare against peers
Open full interactive analysis & DCF →